Study to evaluate the efficacy and safety of human immune globulin in patients with primary immune thrombocytopenia

Registry ID

EUCTR2012-000796-16

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

OCTAPHARMA AG

Start date

2012-07-09

Last update

2026-08-16

Conditions

• Primary Immune Thrombocytopenia (ITP)

Summary

To assess the efficacy of Octagam 10% in correcting the platelet count (PC).

Locations

• , , Czechia
• , , Poland
• , , Germany
• , , Bulgarian Drug Agency

Related clinical trials

• A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)
• A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
• A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
• High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia
• Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults
• An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia

View on source registry